Global Distribution of Novel Rhinovirus Genotype


Global surveillance for a novel rhinovirus genotype indicated its association with community outbreaks and pediatric respiratory disease in Africa, Asia, Australia, Europe, and North America. Molecular dating indicates that these viruses have been circulating for at least 250 years.

Acute respiratory illness (ARI) is the most frequent infectious disease of humans. Ordinary upper respiratory tract infections are usually self-limited; nevertheless, they result in major economic impact through loss of productivity and strain on healthcare systems. Lower respiratory tract infections (LRTIs) are among the leading causes of death in children <5 years of age worldwide, particularly in resource-poor regions (1). Streptococcus pneumoniae and Haemophilus influenzae are important bacterial causes of ARI, although their impact is expected to decline with increasing vaccine coverage. Collectively, however, viruses dominate as causative agents in ARI. Viruses frequently implicated in ARI include influenza virus, respiratory syncytial virus, metapneumovirus, parainfluenza virus, human enterovirus (HEV), and human rhinovirus (HRV).

HRVs are grouped taxonomically into Human rhinovirus A (HRV-A) and Human rhinovirus B (HRV-B), 2 species within the family Picornaviridae (International Committee on Taxonomy of Viruses database [ICTVdb]; http://phene.cpmc.columbia.edu). These nonenveloped, positive-sense, single-stranded RNA viruses have been classified serologically and on the basis of antiviral susceptibility profile, nucleotide sequence relatedness, and receptor usage (2). Phylogenetic analyses of viral protein VP4/VP2 and VP1 coding regions indicate the presence of 74 serotypes in genetic group A and 25 serotypes in genetic group B (2).

Isolated in the 1950s from persons with upper respiratory tract symptoms (2,3), HRVs have become known as the common cold virus because they are implicated in ≈50% of upper respiratory tract infections (4). Large community surveys, including the Virus Watch studies of the 1960–1970s (5), have shed light on some aspects of HRV biology and epidemiology. HRVs were also observed in LRTIs soon after their recognition (3), and data supporting a causative association have accumulated over the past decade (6,7). HRVs have also been implicated in exacerbations of asthma and chronic bronchitis and are increasingly reported in LRTIs of infants, elderly persons, and immunocompromised patients (4).

The Study

The advent of broad-range molecular assays, including multiplex PCR and microarray systems, promises new insights into the epidemiology and pathogenesis of respiratory disease (8,9), given that a laboratory diagnosis is not routinely achieved for a substantial portion of respiratory specimens from symptomatic patients. We recently described the application of a multiplex PCR method for microbial surveillance wherein primers are attached to tags of varying mass that serve as digital signatures for their genetic targets. Tags are cleaved from primers and recorded by mass spectroscopy, enabling a sensitive, inexpensive, and highly multiplexed microbial detection. We used the multiplex MassTag PCR system (10) to investigate respiratory specimens that had tested negative during routine diagnostic assessment. This previous study yielded pathogen candidates in approximately one third of cases, and in 8 cases identified a novel genetic clade of picornaviruses divergent from the previously characterized clades, including HRV-A and-B (8). To assess whether this novel clade cir-
culates outside New York state, where it was discovered in cases of infulenzalike illness (ILI), we investigated respira-
tory specimens from Africa, Asia, Australia, and Europe. In most studies (Africa, Asia), the collecting laboratories
performed MassTag PCR, and inert mass-tagged amplification products were sent for analysis by mass spectrometry
(MS); in other instances (Europe, Australia), inactivated nasopharyngeal swabs or aspirates were sent to New York
for MassTag PCR and MS analysis.

Samples in South Africa were collected through a program for comprehensive surveillance of causes of respira-
tory illness in hospitalized children in the Pretoria area. MassTag PCR was applied to 58 specimens collected
during the 2006 season from symptomatic children in their first year of life with no diagnosis available from previous
clinical laboratory evaluation. Analysis of amplification products by MS yielded positive signal for HEV/HRV in 14 (24%)
samples. Independent amplification and sequence analysis of VP4/2 coding sequence (8) in both laboratories
showed sequences that matched the novel genotype in 4 (29%) samples obtained from patients with LRTIs and res-
piratory distress (Table 1, Figure). Samples collected in Côte d’Ivoire, West Africa, were from symptomatic per-
sons living in the vicinity of Taï National Park. This location was the most remote of our study; residents have lim-
ited contact with other human populations. In this location, 2 (10%) HRV-A were identified in the 52 samples available
for analysis (Table 1, Figure).

In Nepal, viruses of the novel genotype were identified in specimens collected during ILI surveillance or outbreaks
of respiratory disease. Samples from ILI surveillance activities were collected in Kathmandu and Bharatpur. Outbreak
samples were collected in the summer months from camps of >100,000 refugees from Bhutan located in Jhapa, south-
east Nepal. Samples represented all age groups and were collected from December 2005 through July 2006. The novel
genotype was identified by independent molecular typing in both laboratories in 4 (5%) samples (Table 1, Figu-
re). In India, samples from 50 children with ARI, submitted for routine laboratory analysis during the 2007 season,
were evaluated by MassTag PCR. Independent molecular
typing in both laboratories indicated the novel genotype in 3 (6%) samples (Table 1, Figure).

Table 1. Molecular diagnosis of ARI from 7 countries by using MassTag PCR* and VP4/2 sequencing†

<table>
<thead>
<tr>
<th>Country</th>
<th>Season(s)</th>
<th>Samples</th>
<th>Total</th>
<th>Novel clade</th>
<th>HRV-A</th>
<th>HRV-B</th>
<th>HEV</th>
<th>% Male</th>
<th>Age range (mean/median)</th>
</tr>
</thead>
<tbody>
<tr>
<td>South Africa</td>
<td>2006</td>
<td>58</td>
<td>14</td>
<td>4</td>
<td>6</td>
<td>3</td>
<td>1</td>
<td>71</td>
<td>0.4–30 mo (5.6/3)</td>
</tr>
<tr>
<td>Côte d’Ivoire</td>
<td>2006</td>
<td>52</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>22–28 y (25/25)</td>
</tr>
<tr>
<td>Nepal</td>
<td>2005–06</td>
<td>80</td>
<td>17</td>
<td>4</td>
<td>7</td>
<td>5</td>
<td>1</td>
<td>56</td>
<td>0.25–56 y (8.5/3)</td>
</tr>
<tr>
<td>India</td>
<td>2007</td>
<td>50</td>
<td>6</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>83</td>
<td>4–36 mo (17.8/18)</td>
<td></td>
</tr>
<tr>
<td>Australia</td>
<td>2006</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>100</td>
<td>4–6 mo (5/5)</td>
<td></td>
</tr>
<tr>
<td>Denmark</td>
<td>2007</td>
<td>70</td>
<td>7</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>57</td>
<td>1–8 mo (2.9/2)</td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>2003–2006</td>
<td>14‡</td>
<td>14</td>
<td>6</td>
<td>5</td>
<td>3</td>
<td>0</td>
<td>86</td>
<td>1–96 mo (23.2/15.5)</td>
</tr>
</tbody>
</table>

*See (10).
†ARI, acute respiratory illness; HRV, human rhinovirus; HEV, human enterovirus.
‡With previous HRV diagnosis.
Additional sample sets were obtained through main diagnostic laboratories in Western Australia, Denmark, and Spain, representing random respiratory specimens submitted for laboratory analysis. In 1 sample available from Western Australia, the novel genotype was identified in a preterm infant with undiagnosed, wheezy LRTI. The novel genotype was also found in 5 (7%) of 70 samples from Denmark and in 6 (43%) of 14 samples with previously diagnosed HRV infection from Spain (Table 1, Figure).

The 5% overall frequency of the novel genotype across our study samples, representing 34% of all detected picornavirus infections, and its observed global distribution, led us to analyze the accumulating sequence data for insights into their history. Rates of evolutionary change and the Time to the Most Recent Common Ancestor (TMRCA) of the novel clade were estimated by using the Bayesian Markov Chain Monte Carlo approach (BEAST package [14]), applying a relaxed molecular clock with an uncorrelated lognormal distribution of rates, a GTR + I + \Gamma_4 model of nucleotide substitution (determined by MODELTEST [15]), and exponential population growth. Statistical uncertainty in each parameter estimate is expressed as 95% highest probability density (HPD) values. The estimated mean rate of evolutionary change was 6.6 \times 10^{-4} substitutions/site/year (95% HPD = 0.3–14.6 \times 10^{-4} substitutions/site/year; 38 dated samples collected over 32 mo (8,16) (S.R. Dominguez et al., unpub. data). Under this rate the mean TMRCA was estimated at 1,800 y, although with wide variance caused by the short sequence available (95% HPD = 279–5,201 y). Despite the inherent sampling error, this analysis suggests that this third clade of rhinovirus has been circulating for >250 years. The diversity observed within the novel clade and its genetic distance from other HRV/HEV were comparable to those seen for HRV-A, -B, or the HEV species (Table 2).

Conclusions
A clade of picornaviruses recently discovered in New York State is globally distributed and is found in association with community outbreaks of ARI and severe LRTIs of infants. These viruses contribute both to a substantial proportion of previously undiagnosed respiratory illness and to diagnosed, but nontyped cases of HRV infection. Similar viruses were recently characterized also in Queensland, Australia (11); California, USA (12); Hong Kong Special Administrative Region, People’s Republic of China (13); and Germany (16). Our findings indicate the need for further investigation into this third (HRV-C) group of rhinoviruses with emphasis on epidemiology, pathogenesis, and strategies to prevent and ameliorate disease caused by HRV infection.

Acknowledgments
We thank Ashlee N. Bennett and Jeffrey Hui for technical assistance.

This work was supported by National Institutes of Health awards AI062705, AI051292, AI059576, HL083850, and AI57158 (Northeast Biodefense Center–Lipkin), the South African National Health Laboratory Service Research Awards, award PI060532 by Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, the Robert Koch-Institut, and the Max-Planck-Society. Support by the Ivorian Ministries of the Environment and Forests, of Research and of Health, and the Swiss Research Center, Abidjan, is gratefully acknowledged.

Dr Briese is associate director of the Center for Infection and Immunity and associate professor of epidemiology at Columbia University’s Mailman School of Public Health. His research focuses on the molecular epidemiology of viruses, virus-host interactions, and innovative methods for pathogen detection and diagnosis.

References

<table>
<thead>
<tr>
<th>Viruses</th>
<th>HEV-A</th>
<th>HEV-B</th>
<th>HEV-C</th>
<th>PV†</th>
<th>HEV-D</th>
<th>HRV-A</th>
<th>HRV-B</th>
<th>New clade</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEV-A</td>
<td>72</td>
<td>61</td>
<td>63</td>
<td>63</td>
<td>63</td>
<td>59</td>
<td>61</td>
<td>60</td>
</tr>
<tr>
<td>HEV-B</td>
<td>75</td>
<td>64</td>
<td>64</td>
<td>64</td>
<td>59</td>
<td>59</td>
<td>61</td>
<td>59</td>
</tr>
<tr>
<td>HEV-C</td>
<td>75</td>
<td>64</td>
<td>64</td>
<td>64</td>
<td>62</td>
<td>61</td>
<td>65</td>
<td>61</td>
</tr>
<tr>
<td>PV</td>
<td>81</td>
<td>83</td>
<td>83</td>
<td>83</td>
<td>60</td>
<td>60</td>
<td>62</td>
<td>61</td>
</tr>
<tr>
<td>HEV-D</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>HRV-A</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
</tr>
<tr>
<td>HRV-B</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
</tr>
</tbody>
</table>

*HEV, human enterovirus; PV, poliovirus; HRV, human rhinovirus.
†PV may be moved by the International Committee on Taxonomy of Viruses into HEV-C.

Address for correspondence: Thomas Briese, Center for Infection and Immunity, Mailman School of Public Health, Columbia University, 722 West 168th St, 18th Floor, New York, NY 10032, USA; email: thomas.briese@columbia.edu